India, Aug. 3 -- Akebia Therapeutics Inc. (AKBA), on Monday reported the initiation of the Phase 2 basket trial evaluating the safety, efficacy, and pharmacokinetics of Ebribafusp in treating rare complement-mediated kidney diseases.
Rare kidney diseases linked to complement-mediated pathways include IgA nephropathy (IgAN), lupus nephritis (LN), and C3 glomerulopathy (C3G). These affect over 200,000 patients in the U.S. alone, who have previously shown a viable response to complement inhibitors, as the complement C3d in glomeruli, the tubules that filter urine in the kidneys, is a hallmark of several kidney diseases.
The developing drug Ebribafusp is an investigational, anti-C3d factor H fusion protein that has demonstrated some success a...